About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker INCY · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 13, 2026A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thromboc…
NCT07623200 · Essential Thrombocythemia
INCA033989, Best Available Treatment
INCY
Incyte Corporation
Phase 3Recruiting426Jun 15, 2029Registry ↗
Nov 13, 2026A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Muta…
NCT07522073 · Solid Tumors
INCB161734, Placebo
INCY
Incyte Corporation
Phase 3Recruiting588Sep 15, 2028Registry ↗
Nov 13, 2026Study of INCA036978 in Participants With Myeloproliferative Neoplasms
NCT07441694 · Myeloproliferative Neoplasms
INCA036978, Standard disease-directed therapy
INCY
Incyte Corporation
Phase 1Recruiting218May 24, 2030Registry ↗
Nov 13, 2026Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to…
NCT07213973 · Hidradenitis Suppurativa (HS)
Povorcitinib
INCY
Incyte Corporation
Phase 2Recruiting40Mar 25, 2028Registry ↗
Nov 13, 2026A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic…
NCT07124078 · Chronic Graft-versus-host-disease
INCA034176, Best available Treatment (BAT)
INCY
Incyte Corporation
Phase 2Recruiting60Jan 31, 2029Registry ↗
Nov 13, 2026Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
NCT06855498 · Hidradenitis Suppurativa (HS)
povorcitinib
INCY
Incyte Corporation
Phase 3Recruiting600Feb 28, 2028Registry ↗
Nov 13, 2026A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Ho…
NCT06585774 · Chronic Graft-versus-host-disease
INCA034176, Placebo
INCY
Incyte Corporation
Phase 3Recruiting240Sep 28, 2027Registry ↗
Nov 13, 2026A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodu…
NCT06516965 · Prurigo Nodularis
Povorcitinib, Placebo
INCY
Incyte Corporation
Phase 3Active, not recruiting346Sep 28, 2026Registry ↗
Nov 12, 2026Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Su…
NCT06959225 · Hidradenitis Suppurativa
Ruxolitinib Cream, Vehicle Cream
INCY
Incyte Corporation
Phase 3Active, not recruiting580Oct 29, 2026Registry ↗
Nov 9, 2026Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Su…
NCT06958211 · Hidradenitis Suppurativa
Ruxolitinib Cream, Vehicle Cream
INCY
Incyte Corporation
Phase 3Active, not recruiting573Oct 1, 2026Registry ↗
Nov 6, 2026A Study to Assess the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose…
NCT07814404 · Healthy Participants
INCB161734
INCY
Incyte Corporation
Phase 1Completed
was active, not recruiting
10Oct 15, 2026Registry ↗
Nov 6, 2026A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodul…
NCT05764161 · Prurigo Nodularis
Ruxolitinib Cream, Vehicle Cream
INCY
Incyte Corporation
Phase 3Completed190Dec 30, 2024Registry ↗
Nov 5, 2026A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moder…
NCT05620836 · Hidradenitis Suppurativa (HS)
Povorcitinib, Placebo
INCY
Incyte Corporation
Phase 3Completed619Jan 7, 2025Registry ↗
Oct 30, 2026A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With o…
NCT07284849 · CRC (Colorectal Cancer)
INCA33890, Placebo
INCY
Incyte Corporation
Phase 3Recruiting700Dec 29, 2028Registry ↗
Oct 30, 2026Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoi…
NCT07104565 · Immune Thrombocytopenia
INCA000585
INCY
Incyte Corporation
Phase 2Recruiting56Sep 23, 2027Registry ↗
Oct 29, 2026A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutan…
NCT07448155 · Healthy Participants
INCA033989, Bioavailability enhancer
INCY
Incyte Corporation
Phase 1Active, not recruiting
was recruiting
108Nov 14, 2026Registry ↗
Oct 22, 2026A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/M…
NCT06615050 · Graft-versus-host Disease (GVHD)
Tacrolimus (Tac), Methotrexate (MTX)
INCY
Incyte Corporation
Phase 3Recruiting572Jan 17, 2031Registry ↗
Oct 22, 2026Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Rel…
NCT05429268 · Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma
Tafasitamab, Lenalidomide
INCY
Incyte Corporation
Phase 3Active, not recruiting82Mar 30, 2026Registry ↗
Oct 22, 2026To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia…
NCT05090891 · Fibrodysplasia Ossificans Progressiva (FOP)
INCB000928, Placebo
INCY
Incyte Corporation
Phase 2Recruiting98Jul 30, 2027Registry ↗
Oct 20, 2026A Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Advanced/Metastatic…
NCT07862998 · Unresectable Cholangiocarcinoma, Advanced/Metastatic Cholan…
Pemigatinib
INCY
Incyte Corporation
Phase 2Not yet recruiting72Feb 25, 2031Registry ↗
Oct 20, 2026A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma
NCT05888844 · Cutaneous Squamous Cell Carcinoma
INCB099280
INCY
Incyte Corporation
Phase 2Terminated63Sep 28, 2026Registry ↗
Oct 20, 2026A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint I…
NCT05879822 · Advanced Solid Tumor
INCB099280
INCY
Incyte Corporation
Phase 2Terminated73Sep 30, 2026Registry ↗
Oct 15, 2026Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Plat…
NCT07214779 · Ovarian Cancer
INCB123667, Investigator's choice of chemotherapy
INCY
Incyte Corporation
Phase 3Recruiting466Nov 15, 2028Registry ↗
Oct 15, 2026A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Partic…
NCT06388564 · Chronic Graft-versus-host-disease
Axatilimab, Ruxolitinib
INCY
Incyte Corporation
Phase 2Active, not recruiting130Oct 1, 2026Registry ↗
Oct 15, 2026A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Ato…
NCT06238817 · Atopic Dermatitis
Ruxolitinib Cream, Vehicle Cream
INCY
Incyte Corporation
Phase 3Completed241May 21, 2025Registry ↗
Oct 9, 2026A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Do…
NCT07588139 · Healthy Participants
Povorcitinib, Ruxolitinib
INCY
Incyte Corporation
Phase 1Completed24Sep 8, 2026Registry ↗
Oct 9, 2026A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Maligna…
NCT07195916 · Solid Tumors, Hematologic Malignancies
INCA036873
INCY
Incyte Corporation
Phase 1Recruiting280Aug 18, 2028Registry ↗
Oct 9, 2026Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hi…
NCT07049575 · Hidradenitis Suppurativa
Ruxolitinib Cream
INCY
Incyte Corporation
Phase 1Recruiting24Dec 9, 2026Registry ↗
Oct 9, 2026A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old)…
NCT06804811 · NonSegmental Vitiligo
Ruxolitinib Cream, Vehicle Cream
INCY
Incyte Corporation
Phase 3Recruiting250Apr 30, 2027Registry ↗
Oct 6, 2026Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease
NCT05919511 · cGVHD
Non-Interventional
INCY
Incyte Corporation
—Recruiting1,500Oct 15, 2027Registry ↗
Oct 2, 2026A Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Impaired Ren…
NCT07854249 · Renal Insufficiency, Kidney Diseases
INCB161734
INCY
Incyte Corporation
Phase 1Not yet recruiting24Mar 30, 2027Registry ↗
Oct 2, 2026Phase 3 Study of INCB123667 Plus Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance The…
NCT07797283 · Ovarian Cancer
INCB123667, Bevacizumab
INCY
Incyte Corporation
Phase 3Not yet recruiting590May 1, 2032Registry ↗
Oct 1, 2026A Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Hepatic Impa…
NCT07853040 · Hepatic Insufficiency, Liver Diseases
INCB161734
INCY
Incyte Corporation
Phase 1Not yet recruiting24Mar 31, 2027Registry ↗
Oct 1, 2026INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With An…
NCT04455841 · Anemia, Post-essential Thrombocythemia Myelofibrosis
INCB000928, ruxolitinib
INCY
Incyte Corporation
Phase 1/2Completed84Apr 1, 2025Registry ↗
Sep 29, 2026Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or…
NCT03358472 · Head and Neck Cancer
Pembrolizumab, Epacadostat
INCY
Incyte Corporation
Phase 3Completed89Jul 19, 2018Registry ↗
Sep 25, 2026Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metast…
NCT04472429 · Squamous Cell Carcinoma of the Anal Canal
carboplatin, paclitaxel
INCY
Incyte Corporation
Phase 3Completed308Apr 15, 2024Registry ↗
Sep 22, 2026A Study to Evaluate INCA33890 in the Treatment of Circulating Tumor DNA-Positive Stage II/III Micro…
NCT07823322 · CRC (Colorectal Cancer)
INCA33890
INCY
Incyte Corporation
Phase 2Not yet recruiting40May 14, 2029Registry ↗
Sep 15, 2026A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexp…
NCT07023627 · Ovarian Cancer
INCB123667
INCY
Incyte Corporation
Phase 2Recruiting160Apr 27, 2027Registry ↗
Sep 14, 2026A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Non…
NCT06548360 · NonSegmental Vitiligo
Ruxolitinib Cream, Vehicle Cream
INCY
Incyte Corporation
Phase 3Recruiting180Jun 5, 2028Registry ↗
Sep 8, 2026A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring…
NCT06039384 · Advanced Solid Tumors
INCB099280, adagrasib
INCY
Incyte Corporation
Phase 1Terminated6Apr 11, 2025Registry ↗
Sep 4, 2026A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compar…
NCT04680052 · Follicular Lymphoma, Marginal Zone Lymphoma
tafasitamab, rituximab
INCY
Incyte Corporation
Phase 3Active, not recruiting654Feb 23, 2024Registry ↗
Sep 2, 2026A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors
NCT06873789 · Solid Tumors, Advanced Solid Tumors
INCB177054, Retifanlimab
INCY
Incyte Corporation
Phase 1/2Terminated9Jul 29, 2026Registry ↗
Aug 25, 2026A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Ver…
NCT06821542 · Chronic Graft-versus-host-disease
INCA034176, Best Available Therapy (BAT)
INCY
Incyte Corporation
Phase 3Active, not recruiting9May 31, 2028Registry ↗
Aug 25, 2026A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G…
NCT06818812 · Solid Tumors
INCB186748, Cetuximab
INCY
Incyte Corporation
Phase 1Active, not recruiting30Mar 27, 2027Registry ↗
Aug 25, 2026A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate…
NCT06212999 · Hidradenitis Suppurativa (HS)
Povorcitinib
INCY
Incyte Corporation
Phase 3Active, not recruiting617Dec 26, 2026Registry ↗
Aug 25, 2026A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo…
NCT06113445 · NonSegmental Vitiligo
Povorcitinib, Placebo
INCY
Incyte Corporation
Phase 3Active, not recruiting467Feb 24, 2026Registry ↗
Aug 19, 2026A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <1…
NCT06832618 · Atopic Dermatitis
Ruxolitinib, Vehicle Cream
INCY
Incyte Corporation
Phase 3Active, not recruiting159Aug 7, 2026Registry ↗
Aug 17, 2026Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN0239…
NCT04370704 · Melanoma
INCAGN02385, INCAGN02390
INCY
Incyte Corporation
Phase 1/2Completed61Aug 25, 2025Registry ↗
Aug 17, 2026An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studie…
NCT02955940 · Pancreatic Cancer, Colorectal Cancer (CRC)
Ruxolitinib, Capecitabine
INCY
Incyte Corporation
Phase 2Active, not recruiting10Sep 30, 2027Registry ↗
Aug 12, 2026A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative…
NCT06313593 · Myeloproliferative Neoplasms
INCB160058, Standard disease-directed therapy
INCY
Incyte Corporation
Phase 1Active, not recruiting37Oct 9, 2028Registry ↗

The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:10 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances